title: In vitro evidence that commercial influenza vaccines are not similar in their ability to activate human T cell responses.
abstract: We evaluated three commercial trivalent inactivated vaccines (TIVs) from the 2007-2008 season in terms of their ability to elicit in vitro T cell responses. T cell-mediated immunity may offer a more cross-reactive vaccine approach for the prevention of pandemic or epidemic influenza. Human cytotoxic T cell lines demonstrated differences in matrix protein 1 and nucleocapsid protein recognition of autologous target cells. Peripheral blood mononuclear cells stimulated with each of the TIVs showed statistically significant differences between the vaccines in the numbers of IFNgamma producing cells activated. These data suggest that TIV vaccines are not similar in their ability to activate human T cell responses.
authors.affiliation: Center for Infectious Disease and Vaccine Research, University of Massachusetts Medical School, Worcester, MA 01655, USA. mary.co@umassmed.edu
authors.forename: Mary Dawn T
authors.initials: MD
authors.lastname: Co
authors.forename: Laura
authors.initials: L
authors.lastname: Orphin
authors.forename: John
authors.initials: J
authors.lastname: Cruz
authors.forename: Pamela
authors.initials: P
authors.lastname: Pazoles
authors.forename: Karin M
authors.initials: KM
authors.lastname: Green
authors.forename: James
authors.initials: J
authors.lastname: Potts
authors.forename: Anita M
authors.initials: AM
authors.lastname: Leporati
authors.forename: Jenny Aurielle B
authors.initials: JA
authors.lastname: Babon
authors.forename: James E
authors.initials: JE
authors.lastname: Evans
authors.forename: Francis A
authors.initials: FA
authors.lastname: Ennis
authors.forename: Masanori
authors.initials: M
authors.lastname: Terajima
mesh_terms: D000328:Adult; D015496:CD4-Positive T-Lymphocytes / Q000276:immunology; D018414:CD8-Positive T-Lymphocytes / Q000276:immunology; D002460:Cell Line; D016207:Cytokines / Q000096:biosynthesis; D004345:Drug Industry; D005260:Female; D006801:Humans; D053118:Influenza A Virus, H1N1 Subtype / Q000276:immunology; D053122:Influenza A Virus, H3N2 Subtype / Q000276:immunology; D007252:Influenza Vaccines / Q000008:administration & dosage / Q000276:immunology*; D007251:Influenza, Human / Q000276:immunology / Q000517:prevention & control* / Q000821:virology; D007371:Interferon-gamma / Q000096:biosynthesis; D008213:Lymphocyte Activation; D008297:Male; D008875:Middle Aged; D019590:Nucleocapsid Proteins / Q000276:immunology / Q000378:metabolism; D013601:T-Lymphocytes / Q000276:immunology*; D015164:Vaccines, Inactivated / Q000008:administration & dosage / Q000276:immunology*; D014763:Viral Matrix Proteins / Q000276:immunology / Q000378:metabolism
chemical_list: D016207:Cytokines; D007252:Influenza Vaccines; C488936:M1 protein, Influenza A virus; D019590:Nucleocapsid Proteins; D015164:Vaccines, Inactivated; D014763:Viral Matrix Proteins; D007371:Interferon-gamma